{"id":10087,"date":"2021-05-28T10:22:18","date_gmt":"2021-05-28T17:22:18","guid":{"rendered":"https:\/\/depts.washington.edu\/pandemicalliance\/?p=10087"},"modified":"2021-06-01T10:23:00","modified_gmt":"2021-06-01T17:23:00","slug":"effectiveness-of-bnt162b2-and-mrna-1273-covid-19-vaccines-against-symptomatic-sars-cov-2-infection-and-severe-covid-19-outcomes-in-ontario-canada","status":"publish","type":"post","link":"https:\/\/depts.washington.edu\/pandemicalliance\/2021\/05\/28\/effectiveness-of-bnt162b2-and-mrna-1273-covid-19-vaccines-against-symptomatic-sars-cov-2-infection-and-severe-covid-19-outcomes-in-ontario-canada\/","title":{"rendered":"Effectiveness of BNT162b2 and MRNA-1273 COVID-19 Vaccines against Symptomatic SARS-CoV-2 Infection and Severe COVID-19 Outcomes in Ontario Canada"},"content":{"rendered":"<ul>\n<li style=\"font-weight: 400\"><i><span style=\"font-weight: 400\">[Pre-print, not peer-reviewed]<\/span><\/i><span style=\"font-weight: 400\"> COVID-19 mRNA vaccines (Pfizer-BioNTech and Moderna) were 60% effective against symptomatic SARS-CoV-2 infection 14-20 days after the first dose and 91% effective \u22657 days after the second dose in a test-negative study among symptomatic adults in Ontario, Canada between December 2020 and April 2021 (n=324,033). Vaccine effectiveness against severe outcomes was 62% 14-20 days after the first dose and 98% \u22657 days after the second dose. First-dose vaccine effectiveness estimates were lower among adults aged \u226570 years, but comparable to younger individuals after the second dose. Two-dose vaccine effectiveness remained high against B.1.351 and P.1 variants with the E484K mutation.<\/span><\/li>\n<\/ul>\n<p><i><span style=\"font-weight: 400\">Chung et al.\u00a0(May 28, 2021). Effectiveness of BNT162b2 and MRNA-1273 COVID-19 Vaccines against Symptomatic SARS-CoV-2 Infection and Severe COVID-19 Outcomes in Ontario Canada. Pre-print downloaded May 28 from <\/span><\/i><a href=\"https:\/\/doi.org\/10.1101\/2021.05.24.21257744\"><span style=\"font-weight: 400\">https:\/\/doi.org\/10.1101\/2021.05.24.21257744<\/span><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>[Pre-print, not peer-reviewed] COVID-19 mRNA vaccines (Pfizer-BioNTech and Moderna) were 60% effective against symptomatic SARS-CoV-2 infection 14-20 days after the first dose and 91% effective \u22657 days after the second dose in a test-negative study among symptomatic adults in Ontario, Canada between December 2020 and April 2021 (n=324,033). Vaccine effectiveness against severe outcomes was 62%&#8230;<\/p>\n<div><a class=\"more\" href=\"https:\/\/depts.washington.edu\/pandemicalliance\/2021\/05\/28\/effectiveness-of-bnt162b2-and-mrna-1273-covid-19-vaccines-against-symptomatic-sars-cov-2-infection-and-severe-covid-19-outcomes-in-ontario-canada\/\">Read more<\/a><\/div>\n","protected":false},"author":8,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_links_to":"","_links_to_target":""},"categories":[6],"tags":[33],"topic":[31],"class_list":["post-10087","post","type-post","status-publish","format-standard","hentry","category-article-summary","tag-vaccines","topic-vaccines-and-immunity"],"_links":{"self":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/10087","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/comments?post=10087"}],"version-history":[{"count":1,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/10087\/revisions"}],"predecessor-version":[{"id":10088,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/10087\/revisions\/10088"}],"wp:attachment":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/media?parent=10087"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/categories?post=10087"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/tags?post=10087"},{"taxonomy":"topic","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/topic?post=10087"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}